Use of advanced systemic therapy in adolescent patients with moderate to severe atopic dermatitis in the TARGET DERM Registry.
Use of advanced systemic therapy in adolescent patients with moderate to severe atopic dermatitis in the TARGET DERM Registry (Hawaii Derm)
Challenge
Adolescent patients with moderate-to-severe AD represent a high-need subgroup, but real-world data on what proportion of eligible adolescents receive advanced systemic therapy and what characteristics predict AST initiation—versus remaining undertreated—were limited, hindering pediatric AD drug development and label extension planning.
Solution
The TARGET-DERM AD registry was analyzed to compare demographics, disease severity, and clinical characteristics between AST-treated and AST-naïve adolescents (ages 12–17) with moderate-to-severe disease, identifying predictors of AST initiation using logistic regression.
Impact
Establishing that more than half of eligible adolescents remain AST-naïve despite severe disease creates the evidence base for pediatric prescriber education and supports regulatory and commercial strategy for adolescent label extensions of AD biologics and JAK inhibitors.
